IC
GBT

Ikarian Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Ikarian Capital’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,100
Closed -$91K – 343
2020
Q4 		$91K Hold
2,100
– – ﹤0.01% 215
2020
Q3 		$117K Sell
2,100
-100,000
-98% -$6.36M 0.01% 166
2020
Q2 		$6.45M Buy
+102,100
New +$7M 0.51% 59

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital's GBT Position: Q2 2022 in Review

Ikarian Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2022, closing a stake of 49,997 shares — an estimated $1.73M sold.

Ikarian Capital first reported a position in GBT in Q4 2021 and held it in 2 quarters. The position peaked at $4.8M in Q4 2021. 195 funds tracked by Wall St. Rank hold GBT as of Q2 2022.

  • Ikarian Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 49,997 Global Blood Therapeutics, Inc. shares in Q2 2022, an estimated $1.73M.
  • Ikarian Capital first reported a position in Global Blood Therapeutics, Inc. in Q4 2021 and held it in 2 quarters.
  • Ikarian Capital's Global Blood Therapeutics, Inc. position peaked at $4.8M in Q4 2021.
  • 195 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.